You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...

“Novo Nordisk has a rich history of innovation in obesity and diabetes. We are building on our scientific leadership in this space and developing a broad pipeline across various targets and ...

Novo Nordisk said Wednesday it will sell Wegovy ... Studies like the one led by Barber, he said, don’t take into account the expensive work of research and development, or building the ...

Novo Nordisk is doubling down on its collaboration ... gave Novo three cardiovascular assets and set the stage for work on up to 11 programs overall. Novo was primarily focused on cardiovascular ...

Novo Nordisk. Construction work has begun and is expected to be completed in 2028. The investment is expected to create 600 permanent jobs upon completion of the facilities. During the ...